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S_qary As mutations at codon 12 of the Ki-ras oncogne have been shown to occur in 90% of pancreatic
adenocarcinomas, a novel strategy for the detectin of these mutations in panac secretons obtaine at
routine endoscopies was devloped. Ki-ras DNA was amlified and screened for the presen of mutations at
codon 12 with a combination ofdifferent rapid, non-radioctive ecular biology iques Examination of
DNA from cell lines and paraffin-embedded tumour sampes was used to establish and test the strategy
employed. Pancreatic sectin from 27 paits e e ai for te pe of Ki-ras mutations
Mutations at codon 12 Wer detected in 16/16 sretions from patents with histologially carcinoma
and from one patient with a of the bie duct In six patients a mutation identical to the one found in
the pancreatic secionos was also demonstat in paraffi-embedded fine-noole biopsy or surgical sampes
Of the rmaining ten patients (who had panceatitis or cholelithiasis) mutations were not found m nne. Ki-ras
codon 12 mutation was identified in one of these patients however, and mucous cell hyperplaia of panareatic
ducts was found upon histologcal examination These findings establsh Ki-ras polymerase chain reaction
from scto as a valuabk new iocedure for the demonstration of malignant ceSl,
possibly at an early stage of the disease.
The incidence of adenocarcinoma of the pancreas in de-
veloped countries is rising, and it ranks fourth in mortality
among the malignant diseases (Brennan et al, 1989). It is
curable by surgery only when detected early, but most
patients present with incurable disease. Therefore, early diag-
nosis by a sensitive and specific test could greatly reduce
mortality from this cancer. Screening employing radiological
methods such as computerised tomographic (CT) scans is far
too costly to be practicable, and serum markers such as CA
19-9 are neither specific nor sensitive enough to be employed
as screening tests. Once symptoms and laboratory tests in a
patient point towards carcinoma of the pancreas, radiological
tests such as abdominal ultrasound or CT scan may show
lesions in the pancreas, and usually confirmation by endo-
scopic retrograde cholangiopancreatography (ERCP) is
sought, demonstrating stenosis or complete obstruction of
the pancreatic duct. However, such radiological tests may not
always discriminate reliably between chronic inflammation of
the pancreas and carcinoma.
The large majority (approximately 90%) of pancreatic
adenocarcinomas harbour mutations in codon 12 of the Ki-
ras gene. This gene belongs to the family of p21-ras genes
that code for G-proteins, which are essential for intracellular
signalling and thereby cellular proliferation. Mutations in the
Ki-ras gene have been described at codons 12, 13 and 61.
These mutations lead to a constitutional activation of the
protein in the GTP-bound state and seem to be an essential
step in the development of many human cancers (Bos, 1990).
Since mutations at codon 12 of the Ki-ras gene occur early in
the development of pancreatic adenocarcinoma (Almoguera
et al., 1988) and have been described in premalignant mucous
cell hyperplasia of the pancreas (Yanagisawa et al., 1993), we
decided to use these oncogene mutations as tumour markers.
We have used a sensitive polymerase chain reaction (PCR)-
based test to analyse pancreatic secretions obtained during
routine endoscopic examinations and present data obtained
from 27 patients examined by ERCP. ERCP was performed
because the clinical diagnosis of carcinoma of the pancreas,
inflammation of the pancreas or bile stone had been
made.
We show that a stepwise combination of non-radioactive
PCR screening tests with different levels of sensitivity pro-
vides reproducible and interpretable results within 1-2 days.
In this clinical series the possible usefulness of this test was
most evident in three patients in whom a diagnosis by con-
ventional clinical tests was not possible, and the PCR-based
preoperative diagnosis was confirmed at laparotomy.
Patie.s aad metho&
Patients
Pancreatic secretions and bile fluid were collected from 27
patients during routine endoscopic examinations after instil-
lation of contrast media into the pancreatic and bie ducts.
Patients' data are presented in Table I. The diagnosis 'car-
cinoma of pancreas' was based on clinical and typical radio-
graphic findings (ERCP, CT scan) and was confirmed by
histopathological examination (fine-needle biopsy, laparo-
tomy) if possible. Biopsy material was not always available
since surgery (or autopsies) was not performed in all
cases.
Preparation ofsamples
Pancreatic secretions (approximately 1 ml) were collected into
Eppendorf tubes and centrifuged at high speed in a micro-
fuge (Eppendorf). The pellet was resuspended in 50 l of
TEN (10mM Tris-HCI, 1 mM EDTA, 100mM sodium
chloride) and incubated for 1 h in a 55C water bath with
10iLg of proteinase K (Boehringer Mannheim). After boiling
for 15min to inactivate the proteinase, samples were stored
at -70-C.
Polymerase chain reaction
Special precautions, including UV irradiation of reaction
tubes, handling PCR reagents and products in different
rooms and pipetting PCR reactions under a laminar air flow
hood, were taken to avoid contamination. Appropriate con-
trols were included in all reactions to check for the presence
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Tabie I Clinical data and PCR results of 35 samples from 26 patients examined by Ki-ras PCR
Patient Diagnosis Material Southern SSCP biriched PCR
no. Sex by ERCP Histology tested blot result Plasmid sequence RFLP sequence
3 Female Normal ND PS Positive WT GGT (7/7) ND GGT
Female
Female
Female
P Caa
P Caa
A Panc
23 A Female P Ca
23 B Female P Ca
26 A Male
26 B Male
P Ca
P Ca
ND
P Ca
P Ca
D chol Ca D chol Ca
D chol Ca D chol Ca
27 Female P Ca P Ca
29 Male P Ca NA
30 Female Cholelithiasis ND
32 A Male
32 B Male
33 Male
P Ca
P Ca
P Ca'
34 A Female P Cac
34 B Female P Ca
Male
Male
Male
40 Male
Female
Female
Female
Male
Male
Male
Male
Female
Female
Female
Male
Female
Female
Female
Male
Male
P Ca
P Ca
P Cad
P Ca
P Ca'
P Cae
P Ca'
P Ca
P Ca
P Ca
P Ca
Ca
Ca
Ca
Pa Ca
P Ca
A Panc
P Ca
A Panc
A Panc
P Ca
P Ca
Ch Panc
P Ca
P Ca
P Ca
P Ca
Patient died
P Ca
P Ca
P Ca
P Ca
Meta lung Ca
Patient died
Patient died
P Ca
Inflammation
Inflammation
Inflammation
Inflammation
Inflammation
Lymphoma
P Ca
ND
ND
PS Positive MUT GAT (1/3)
GGT (2/3)
Bile Positive MUT GGT (3/3)
PS Positive WT GGT (7/7)
PS Positive WT GGT (10/10)
Paraffin Positive MUT ND
PS Positive MUT GGT (6/6)
Bile Positive WT GGT (5/5)
Bile Positive WT ND
PS Positive MUT ND
PS Positive WT ND
PS Positive MUT GGT (7/7)
Paraffin Positive MUT ND
PS Positive WT GGT (8/8)
PS Positive MUT GGT (8/8)
Paraffin Positive WT ND
PS
PS
PS
Positive
Positive
Positive
Wr GGT (6/6)
WT GGT (9/9)
MUT GGT (4/4)
PS Positive WT GGT (7/7)
PS
FNB
Surgery
Positive
Positive
Positive
PS Positive
PS Positive
Stent Positive
PS Positive
PS Positive
FNB Positive
FNB Positive
Bile
PS
PS
PS
PS
PS
Positive
Positive
Positive
Positive
Positive
Positive
MUT
MiTf
MiTf
WT
MUT
MiTf
WIT
ND
ND
ND
ND
ND
ND
ND
WT ND
WI ND
WI ND
WT
WT
WT
MifT
WI
WI
ND
ND
ND
ND
ND
ND
MUT GAT/GGT
MUT GAT/GGT
WT GGT
NA NA
NA GAT/GGT
MUT NA
MUT GTTIGGT
MUT GGT/GAT
MUT GGT/GAT
MUT GGT
NA GAT/GGT
MUT GAT/GGT
ND GGT
MUT GTT/GGT
MUT GTT/GGT
MUT
MUT
MUT
MUT
MUT
MUT
MUT
WIT
MifT
MUfT
WT
MifT
MUT
MiTf
WT
WT
WI
MifT
ND
WT
GAT/GGT
AGT/GGT
GAT/GGT
GGT
CGT/GGT
CGT/GGT
CGT/GGT
GGT
GGT/GTT
GGT/GTT
AGT/GGT
GGT
GGT
GGT
GGT
ND
ND
GAT/GGT
ND
ND
'Pancreatic secretions and bile secretions were available from this patient. Molecular results are shown in Figure 1. bThe diagnosis of
carcinoma of the pancreas was made on the basis of ERCP findings. At laparotomy, a chronically inflamed pancreas with pancreaticolithiasis
was found. ERCP results (Figure 2a) and molecular results (Figure 2b) showed WT Ki-ras only. 'Mokeuar results are shown in Figure 3.
dMolecular results are shown in Figure 4. 'This patient presented with an asymptomatic pancreatic mass on ultrasound and CT scan
examination. An unequivocal diagnosis by ERCP or fine-needle biopsy was not possible. Carcinoma of the pancreas was diagnosed at
laparotomy. CT scan and molecular results are shown in Figure 5. ERCP, endoscopic retrograde cholangiopancreatography; SSCP,
single-strand conformation polymorphism; PCR, polymerase chain reaction; NA, not available; ND, not done; P Ca, carcinoma of pancreas;
D, cho Ca, carcinoma of bile duct; A Panc, acute pancreatitis; Ch Panc, chronic pancreatitis; PS, pancreatic secretions; paraffin,
paraffin-embedded tumour DNA; FNB, fine-needle biopsy of tumour, WT, wild-type band pattern; MUT, mutant band pattern.
of contamination. A 10ftl aliquot of the proteinase-digested
DNA from pancreatic secretions served as a template for
PCR. The reaction volume was 50 1.1 containing 50 mM
potassium chloride, 1.5 mM magnesium chloride, 10 mM Tris-
HC1, 0.1 mg ml1' gelatin, 200IAM of each dNTP (Pharmacia)
and 20pmol each of primers K-ras 12-13-3' and 12-13-5'.
After an initial denaturation step at 95C for 5 min, 2.5 units
of Taq polymerase (Boehringer Mannheim) were added and
amplification was performed for 40 cycles with denaturation
at 94C for 1 min, annealing at 56'C for another minute and
extension at 72C for I min. After a final extension at 72C
for 8 min, a second, identical PCR was performed with 0.5 IlI
of the first PCR serving as template in a 50pl reaction to
obtain specific PCR products suitable for single-strand con-
formation polymorphism (SSCP) analysis. Thirty per cent of
the PCR product was analysed on a 2% agarose gel to check
for the presence of the 117 bp product. PCR products were
blotted by alkali transfer (Sambrook et al., 1989) to nylon
membranes (Boehringer Mannheim), followed by hybridisa-
tion to a 5'-end-labelled oligonucleotide (K-ras-12-Hybe) at
60(C in a buffer containing 6xSSC, 1OmM EDTA, 5x
Denhardt's, 0.5% SDS and I00ILgml'- denatured salmon
sperm DNA. Washing was performed to a stringency of
2 x SSC/0. 1% SDS at 60-C for 15 min. Filters were exposed
to Kodak X-omat X-ray film and developed after an over-
night exposure.
Single-strand conformation polymorphismn
One per cent of the PCR product was denatured by boiling
for 10min in 50% deionised formamide, rapidly cooled on
ice and loaded onto a prewarmed 20% homogeneous
PHAST-polyacrylamide gel (Pharmacia) with native buffer
strips. SSCP analysis was performed at 23C with a setting of
400V, 5mA and I W with a prewarm phase of 30mi,
1 min of loading at lower voltage and 30min analysis.
Automated silver staining was performed according to the
manufacturer's instructions (Pharmacia). Gels were air dried
for 2 days and mounted on 35 x 35 mm slide frames.
10 A
10 B
13
35
37
38
A
B
C
A
B
C
41
41
41
43
46
48
50
51
51
51
54
55
56
57
60
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Cloning and sequencing
Thirty per cent of the PCR product was purified by agarose
gel electrophoresis and silica gel purification (QuiaEx). After
poly-dGTP tailing of the insert (Boehringer Mannheim DNA
tailing kit), hybridisation to a KpnI-PstI (Boehringer
Mannheim)-digested, poly-dCTP-tailed plasmid (pTZ) was
performed for 1 h at 37°C. Competent DH5a bacteria were
transformed, and colonies were picked and amplified in Luria
broth (LB)-ampicillin medium. DNA was extracted by an
alkali lysis miniprep method (Sambrook et al., 1989), and
inserts were sequenced using the Sequenase (United States
Biochemical) kit and [32PJdATP or [35SjdATP.
Enrichment PCR
Approximately I tg of DNA was amplified by PCR for 15
cycles with 100 ng each of primers K-ras-12-13-5'-BstNl and
12-13-3'WT in a volume of 100pl. Five per cent of the PCR
product was digested with 20 units of BstNI enzyme (New
England Biolabs) in a volume of 20id at 60'C for 3 h, and
10IL of the digest was used as template for a second round
of PCR with 150 ng each of primers K-ras-12-13-3'-BstNl
and 12-13-5'-BstNI in a volume of 50g1 A 5 il volume of
this PCR product was digested for 2 h in volume of 35 jil and
analysed on a 15% native polyacrylamide gel.
Cy cle sequencing
Sixty per cent of the final enrichment PCR product was
purified on a Microcon-30 column (Amicon), and 2pl of the
concentrated product was sequenced using the Sequitherm
cycle sequencing kit (Biozym Diagnostik) using the 5' kinase-
labelled oligonucleotide K-ras-12-13-3' as sequencing
primer.
Oligonucleotide primer sequences (Jordano & Perucho, 1987)
K-ras-12-13-3': 5'-TGT TGG ATC ATA TTC GTC CA-3'
K-ras-12-13-5': 5'-CCT GCT GAA AAT GAC TGA AT-3'
K-ras-12-Hybe: 5'-CCT ACG CCA CCA GCT CCA AC-3'
K-ras-12-13-3'-internal: 5'-GTC CAC AAA ATG ATT CTG
AA-3'
K-ras-12-13-3'-WT: 5'-TCA AAG AAT GGT CCT GCA CC-
3'
K-ras-12-13-3'-BstNl: 5'-TCA AAG AAT GGT CCT GGA
CC-3'
K-ras-12-13-5'-BstNl: 5'-ACT GAA TAT AAA CTT GTG
GTA GTT GGA CCT-3'
Results
A non-radioactive SSCP assay to detect point mutations at
codon 12 of the Ki-ras gene was established using peripheral
blood lymphocyte DNA, tumour cell line DNA and paraffin-
embedded pancreatic adenocarcinoma tissues (Table II).
Different mutations showed a different migration pattern and
the SSCP assay was able to detect these mutations reliably by
showing aberrant bands. Five out of five pancreatic
adenocarcinoma tissues showed mutations at codon 12 of
Ki-ras, as assessed by SSCP and plasmid sequencing (data
not shown). These mutations occurred at the second base of
codon 12 and involved shifts from G to T or A, confirming
previously published results (Tada et al., 1991). Mutations
were not seen in the T-cell line Jurkat and in normal
peripheral blood lymphocytes (PBLs), whereas the pancreatic
adenocarcinoma cell line Paka showed a typical mutation at
codon 12.
Subsequently, Ras sequences were successfully amplified
from 28 secretions obtained during ERCP (27 from the
pancreatic duct and one from the bile duct), as assessed by
agarose gel analysis and Southern blot. However, since the
sensitivity of the SSCP assay had been determined to be 1:10
(i.e. the ability to detect one mutated sequence in nine wild-
type sequences) in dilution experiments (data not shown), we
were not surprised to find that only 11/16 PCR products
obtained from secretions from putative carcinomas (biopsies
not included) showed an aberrant SSCP migration pattern
(Table I). Neither secretions from acute pancreatitis (n = 3)
or chronic pancreatitis (n = 5) nor secretions from normal
pancreas (n = 6) or cholelithiasis (n = 6) showed aberrant
SSCP patterns (Table I and data not shown). Sequencing of
cloned PCR products was even less sensitive, with only one
mutated plasmid clone out of 107 sequenced clones from 12
patients with carcinoma showing a mutation (Table I. Figure
1. patient 10).
Therefore, an enriched PCR strategy (Kahn et al., 1991)
utilising primers with single base substitutions to introduce a
novel restriction site close to the wild-type codon 12 was
established. PCR products after two amplification rounds
showed the artificially introduced PCR-RFLP (restriction
fragment length polymorphism) only in wild-type but not in
mutated template DNA. All PCR products were sequenced
directly to prove the successful incorporation of the single
base substitution as well as to confirm the presence of muta-
tions and record the type of mutation present. The detection
of different mutations at codon 12 (Table I) in different
secretions argues against the presence of contaminated PCR
products. Mutations at codon 12 were detected in 16/16
reactions from secretions of patients with histologically
confirmed carcinoma with this method, in accordance with
previously published data on the frequency of these muta-
tions (Almoguera et al., 1988). A mutation was also found in
the bile fluid from a patient with a histologically confirmed
carcinoma of the bile duct. The detection of identical codon
12 mutations in pancreatic secretions and in a subsequently
resected pancreatic carcinoma (in three cases) or in bile (one
case) (Table I, patients 32. 34, 41 and 10) also strongly
Table H Ras-PCR results of tumour DNA from five paraffin-embedded pancreatic
adenocarcinomas, two cell lines and normal peripheral blood lymphocytes
Pathology Plasmid Enriched
no. Histology sequence sequence SSCP result RFLP
P I P Ca ND CGT/GGT MUT MUT
P II P Ca GAT (2/9) GAT/GGT MUT ND
P III P Ca GTT (1 9) GTTIGGT MUT ND
P IV P Ca ND ND MUT MUT
P V P Ca ND GTT,/GGT MUT MUT
Type of Plasmid Enriched PCR
Sample Origin sample SSCP sequence sequence RFLP
Jurkat T cell Cell line WT ND GGT WT
PBLs Lymphocyte Normal donor WT ND GGT WT
Paka Pancreas Ca Cell line MUT GTT GTT MUT
All five tumours as well as the pancreatic carcinoma cel line Paka show mutations at codon 12 of
Ki-ras, whereas no mutations are detected in the T cell line Jurkat and normal PBLs. Abbreviations
as in Table I.DIAGNOSIS OF PANCREATIC ADENOCARCINOMA BY PCR 281
Plasmid sequencing Cyclesequencng
CTAG CTAG C T A G
j GGT
GGT
GAT
ps Bile
RFLP SSCP
.-o-MUT
~-W-
MT
Double
strand
143 bp _
114 -
GAT
- MUT
-WT
ps Bile
Bile Ps
Figwe 1 Molecular results of patient 10. Material obtained from patient 10 was examined by plasmid cloning and sequencing (top
left), SSCP analysis (bottom left), direct cycle sequencing of PCR products (top right) and RFLP of enriched PCR (bottom right;
see Matenals and methods section for further details). A mutation at codon 12 of Ki-ras was detected in both pancreas and bile
secretions; however, the percentage of mutated alleles was higher in bile fluid as evidenced by the nearly complete disappearance of
wild-type bands in cycle sequencing and RFLP analysis. SSCP analysis demonstrated two wild-type (WT) bands corresponding to
both DNA strands as well as two mutated bands and a lower band corresponding to non-denatured PCR products. For technical
reasons (loading at gel running on a low voltage setting), on the PHAST system, the strong wild-type bands appear as
doublets.
argues against the presence of contaminated products and
confirms that the mutations found in pancreatic secretions
indeed derived from the tumour.
Based on these findings, a rapid and economical screening
strategy was developed. Pancreatic secretions are first
examined by PCR and SSCP analysis. This approach is rapid
(6 h from centrifugation of secretions) and simple. To
confirm these results in an independent reaction (which may
be important in the clinical setting) and in cases where no
abnormal strands are seen, an enrichment PCR with RFLP
analysis is performed, followed by confirmatory direct
sequencing to record the type of mutation present. The latter
procedure is the only one in which radioactive isotopes are
used.
The potential value of this approach is shown by the
findings in three patients from our preliminary series. Results
obtained from molecular biology examinations were not
communicated to clinicians and therefore did not influence
clinical decision making.
1. Patient no. 33 was thought to have adenocarcinoma of
the pancreas by radiological criteria (Figure 2a). Neither
SSCP nor enriched PCR was able to detect a mutation
(Figure 2b). Subsequent histological examination of the
pancreas after laparotomy showed a chronically inflamed
organ without evidence of malignancy. Narrowing of the
duct had been caused by concrements.
2. Patient no. 41 was found to have a small mass in the tail
of the pancreas on routine ultrasound examination with-
out any clinical symptoms or abnormal laboratory
findings. ERCP showed a partially obstructed pancreatic
duct and CT scan examination confirmed the presence of
a mass (Figure 5a). However, histological examination of
a fine-needle biopsy showed only necrotic tissue and was
therefore unable to establish an unequivocal diagnosis.
PCR-SSCP clearly demonstrated the presence of aber-
rant bands in the secretion (approximately 20% aberrant
bands) and the fine-needle biopsy (>50%; Figure Sb).
This strongly suggested the presence of a malignant
lesion, which was confirmed on laparotomy and SSCP
examination of pancreas tissue.
3. Patient no. 51 had a history of chronic pancreatitis with
extensive narrowing and deformation of the pancreatic
ducts and recurrent clinical symptoms. Findings on
ERCP suggested the possible presence of a carcinoma,
and therefore a surgical resection was performed.
PCR-RFLP from pancreatic secretions and fine-needle
biopsy material demonstrated the presence of a mutation,
whereas SSCP and direct sequencing of enrichment PCR
products showed wild-type only, suggesting the presence
of a small proportion of mutated cells. Histology demon-
strated extensive changes due to inflammation and the
presence of mucous cell hyperplasia of pancreatic ducts.
The presence of Ki-ras mutations in changes of this type
has been shown previously (Yanagisawa et al., 1993).
Dcoi
The advent of DNA amplification by polymerase chain reac-
tion (Saki et al., 1988) has changed diagnostic strategies in a
number of diseases, ranging from hereditary diseases such as
cystic fibrosis (Kerem et al., 1990) to infectious diseases such
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Figure 2 a. ERCP X-ray picture of patient 33. Complete ob-
struction of the pancreatic duct consistent with carcinoma of the
pancreas was seen at the ERCP examination. At laparotomy,
chronic inflammation of the pancras with numerous pancreatic
stones was diagnosed. b, Cycle sequencing and SSCP demon-
strated WT Ki-ras only (GGT at codon 12).
as tuberculosis (Brisson et al.. 1989) or human immuno-
deficiency virus infection (Laure et al., 1988). By employing a
ras oncogene PCR for the detection of colorectal adenocar-
cinoma cells from the stool of patients, Sidransky et al.
(1992) have demonstrated that oncogene point mutations in
certain tumours may serve as fairly sensitive and specific
tumours markers. However, the rate of ras mutations in
colonic carcinomas is only approximately 50%, whereas the
great majority of pancreatic adenocarcinomas harbour Ki-ras
codon 12 mutations. Therefore, the demonstration of these
mutations in pancreatic secretions obtained at routine endo-
scopies provides a highly sensitive and specific new tumour
test. This test can be performed within 1-2 days without the
need for handling of radioactive substances except for the
confirmatory sequencing step. The stepwise application of
two different PCR approaches with increasing sensitivity
allows rapid and economical processing of samples and also
allows for 'internal controls' since two independent PCR
reactions are performed on each sample and the actual se-
quence is always read, thereby minimising the risk of con-
tamination and introduction of PCR errors.
The differentiation between radiographic findings caused
by chronic inflammation or carcinoma is sometimes very
difficult, as these two diseases may share similar clinical and
radiological characteristics (Warshaw & del Castillo, 1992),
and the risk of developing carcinoma of the pancreas in
patients with chronic pancreatitis is significantly elevated
(Lowenfels et al., 1993). Therefore, the development of this
novel tumour marker test may be a significant step towards
the early identification of patients with or at risk of develop-
ing carcinoma of the pancreas. As evidenced in patient 51 of
our series, putative premalignant lesions in patients with
chronic inflammation may be detected by the PCR test.
Figue 3 Molecular results of patient 34. SSCP (top left), RFLP
of enriched PCR (top right, showing undigested and digested
PCR product) and direct PCR sequencing showed a mutation
(GGT to GTI) at codon 12.
SSCP RFLP
i_wr
MUT
I WT
_ Double
strand
WTr-
*-143
-114
Cycle sequencing
G A T C
GGTr
GAT
Fiue 4 Molecular results of patient 38. A mutation at codon
12 of Ki-ras (GGT to GAT) was demonstrated by SSCP analysis,
RFLP digestion and direct PCR sequencing.
a
Cycle
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Figur 5 a. Abdominal CT scan of patient 41. A mass in the taill
of the pancreas was shown by ultrasound and CT scan. ERCP
showed narrowing and complete obstruction of the duct of Wir-
sung. b. Molecular results of patient 41. SSCP and RFLP results
of DNA obtained at surgery, by fine-needle biopsy and from
pancreatic secretions all demonstrated the presence of a mutation
at codon 12 of Ki-ras. The sample obtained by FNB showed the
highest percentage of mutated alleles.
However, a small number of carcinomas may not harbour
ras mutations, or the PCR test may fail to detect a small
proportion of carcinomas with the mutation. Also, we cannot
yet fuly evaluate the incidence of false-positive results caused
by PCR artefacts and contamination. Therefore, a correla-
tion between PCR results and pathological findings in a
prospective study with a large number of patients will pro-
vide information about the reliability of this PCR test. A
multicentre study is currently under way in Germany.
Radiological examinations and fine-needle biopsy patho-
logy - where available - may not be able to provide un-
equivocal results in asymptomatic patients since the biopsy
often shows only necrotic tissue in patients with carcinoma.
In one such patient (no. 41) Ki-ras PCR proved the malig-
nant nature of the lesion by showing that most of the DNA
extracted from the necrotic tissue was mutated at codon 12.
Therefore, our new diagnostic approach may also signifi-
cantly enhance the diagnostic value of fine-needle biopsies
since biopsy tissue or aspirates may not always be available
in quantities sufficient for pathological examination. Our
results indicate that the combination of SSCP and enrich-
ment PCR followed by digestion or direct sequencing from
pancreatic secretions presents a reliable and practical method
for the demonstration of ras mutations in carcinoma of the
pancreas.
Tada et al. (1993) recently presented results utilising a
novel, hitherto unpublished allele-specific PCR method to
detect Ki-ras mutations in the pancreatic juice from six
patients with pancreatic carcinoma. In contrast to the
strategy employed by us, mutations other than the ones
detected by mutant-specific primers cannot be detected, and
sequencing of PCR products obained from pancreatic juice
to confirm the presence of mutations and control for
contamination is not possible. Rather. separate, different
reactions from tumour biopsies have to be prepared for
sequencing and may not always be available in the clinical
setting. We have never seen two different mutations in the
same patient as described by Tada et al. (1993) for 3/6
patients, nor has this been described in the published
literature. Further series will be needed to compare the two
approaches in terms of their practical value and reli-
ability.
Once more, a DNA-based amplification technique
broadens the spectrum of diagnostic tests available and may
aid in the early diagnosis of cancer when conventional tests
leave uncertainty. Examination of a large series of pancreatic
secretions obtained at ERCP and, possibly, duodenal secre-
tions obtained at gastroduodenoscopy as well as DNA ex-
tracted from penrpheral blood cells or serum will provide
further information about the clinical applicability of Ki-ras
PCR for the diagnosis of pancreatic adenocarcinoma.
We gratefully acknowledge the support of the clinicians who cared
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